Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Aug 10;12:721887. doi: 10.3389/fimmu.2021.721887

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Zeller, Bogner, Kiefer, Braig, Winninger, Fricke, Karasu, Peter, Huber-Lang and Eisenhardt

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Inhibition of C5aR1 impedes phagocytosis of zymosan dramatically in whole blood leukocytes, while OmCI does not. Blood was treated with 10 µg/mL C5aR1 antagonist PMX53 (A–C) and C5 inhibitor OmCI (D–F), respectively. 15 min before the exposure to the phagocytosis targets, the relevant inhibitor was added, and phagocytosis was assessed subset-specifically. PMX53-treated neutrophils (A), classicals (B), and non-classicals (C) showed reduced phagocytotic activity. However, neutrophils were affected by C5aR1 antagonism by PMX53 in particular (P < 0.05 *, P < 0.01 **, < 0.001 ***, (A). PMX53 reduced phagocytosis significantly in both monocyte subsets with exception for early time points (B, C). However, we did not find the C5 inhibitor OmCI to reduce the phagocytotic activity in any subtype and time point significantly except for the 5 min time-point in neutrophils (D–F).